Vicore Pharma

Stockholm, March 09, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following investor conferences:

• DNB Carnegie Healthcare Conference
  Location: Stockholm, Sweden
  Format: Presentation and 1×1 meetings
  Presentation Date and Time: Thursday, March 12 at 9:10 AM CET
  Participant: Mikael Nygård, COO

• 10^th Annual Nordic-American Healthcare Conference
  Location: New York, USA
  Format: Presentation and 1×1 meetings
  Presentation Date and Time: Wednesday, March 25 at 2:00 PM EST
  Participant: Megan Richards, VP of IR and Comms

For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma 
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
 
Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com